CN1758910A - 异喹啉衍生物治疗癌症和map激酶相关疾病的用途 - Google Patents

异喹啉衍生物治疗癌症和map激酶相关疾病的用途 Download PDF

Info

Publication number
CN1758910A
CN1758910A CNA2004800065706A CN200480006570A CN1758910A CN 1758910 A CN1758910 A CN 1758910A CN A2004800065706 A CNA2004800065706 A CN A2004800065706A CN 200480006570 A CN200480006570 A CN 200480006570A CN 1758910 A CN1758910 A CN 1758910A
Authority
CN
China
Prior art keywords
substituted
phenyl
alkyl
unsubstituted
lower alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2004800065706A
Other languages
English (en)
Chinese (zh)
Inventor
D·B·巴特
G·博尔德
S·金
T·M·拉姆齐
M·L·萨比奥
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of CN1758910A publication Critical patent/CN1758910A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Quinoline Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
CNA2004800065706A 2003-03-11 2004-03-10 异喹啉衍生物治疗癌症和map激酶相关疾病的用途 Pending CN1758910A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45362403P 2003-03-11 2003-03-11
US60/453,624 2003-03-11

Publications (1)

Publication Number Publication Date
CN1758910A true CN1758910A (zh) 2006-04-12

Family

ID=32990797

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2004800065706A Pending CN1758910A (zh) 2003-03-11 2004-03-10 异喹啉衍生物治疗癌症和map激酶相关疾病的用途

Country Status (22)

Country Link
EP (1) EP1603566B1 (enExample)
JP (1) JP2006519807A (enExample)
KR (1) KR20050108383A (enExample)
CN (1) CN1758910A (enExample)
AT (1) ATE421324T1 (enExample)
AU (1) AU2004218914A1 (enExample)
BR (1) BRPI0408257A (enExample)
CA (1) CA2518530A1 (enExample)
DE (1) DE602004019193D1 (enExample)
ES (1) ES2318276T3 (enExample)
HR (1) HRP20050788A2 (enExample)
IS (1) IS8064A (enExample)
MA (1) MA27724A1 (enExample)
MX (1) MXPA05009687A (enExample)
NO (1) NO20054647L (enExample)
PL (1) PL1603566T3 (enExample)
PT (1) PT1603566E (enExample)
RU (1) RU2325159C2 (enExample)
TN (1) TNSN05223A1 (enExample)
TW (1) TW200501955A (enExample)
WO (1) WO2004080464A1 (enExample)
ZA (1) ZA200506571B (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103038364A (zh) * 2010-03-09 2013-04-10 达纳－法伯癌症研究所公司 诊断和治疗具有或发展对于第一种癌症治疗的抗性的患者中的癌症的方法
CN103435430A (zh) * 2013-08-08 2013-12-11 四川大学 一种还原酰胺类化合物的方法

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004247626B8 (en) 2003-05-15 2011-05-19 Arqule, Inc. Imidazothiazoles and imidazoxazole derivatives as inhibitors of p38
PE20050952A1 (es) * 2003-09-24 2005-12-19 Novartis Ag Derivados de isoquinolina como inhibidores de b-raf
WO2006010082A1 (en) 2004-07-08 2006-01-26 Arqule, Inc. 1,4-disubstituted naphtalenes as inhibitors of p38 map kinase
US8178672B2 (en) 2004-10-19 2012-05-15 Arqule, Inc. Synthesis of imidazooxazole and imidazothiazole inhibitors of p38 MAP kinase
CN101160131A (zh) * 2005-02-25 2008-04-09 诺瓦提斯公司 Bcr-abl和raf抑制剂的药物组合产品
JP5049970B2 (ja) * 2005-07-26 2012-10-17 サノフイ Ｒｈｏ−キナーゼ阻害剤としてのシクロヘキシルアミンイソキノロン誘導体
US8318941B2 (en) 2006-07-06 2012-11-27 Bristol-Myers Squibb Company Pyridone/hydroxypyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors
JP2009077712A (ja) * 2007-09-11 2009-04-16 F Hoffmann La Roche Ag Ｂ−Ｒａｆキナーゼ阻害剤に対する感受性についての診断試験
US20110152770A1 (en) 2009-07-30 2011-06-23 Tandem Diabetes Care, Inc. Infusion pump system with disposable cartridge having pressure venting and pressure feedback
US9056855B2 (en) * 2010-10-28 2015-06-16 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds
KR102119943B1 (ko) 2018-05-23 2020-06-05 주식회사 포스코 시편배치유닛 및 이를 포함하는 도장밀착성 실험장치
US20210275516A1 (en) * 2018-07-02 2021-09-09 Ecole Polytechnique Federale De Lausanne (Epfl) Lactate enhancing compounds and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW544448B (en) * 1997-07-11 2003-08-01 Novartis Ag Pyridine derivatives
BR9912938B1 (pt) * 1998-08-11 2011-06-28 derivados de isoquinolina, composição que os compreende, processo para preparação e uso dos mesmos.
GT200000158A (es) * 1999-09-28 2002-03-16 Piridinas y piridacinas sustituidas con actividad de inhibicion de angiogenesis.
WO2001058899A1 (en) * 2000-02-09 2001-08-16 Novartis Ag Pyridine derivatives inhibiting angiogenesis and/or vegf receptor tyrosine kinase
WO2002060392A2 (en) * 2001-01-31 2002-08-08 Synaptic Pharmaceutical Corporation Use of gal3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods
EP1364212B1 (en) * 2001-03-02 2011-02-02 GPC Biotech AG Three hybrid assay system
MXPA04005561A (es) * 2001-12-21 2004-12-06 Bayer Pharmaceuticals Corp Terapias de combinacion anti-angiogenesis que comprenden derivados de piridazina o piridina.
US7220775B2 (en) * 2002-08-07 2007-05-22 H. Lundbeck A/S Compound useful for the treatment of neuropathic pain

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103038364A (zh) * 2010-03-09 2013-04-10 达纳－法伯癌症研究所公司 诊断和治疗具有或发展对于第一种癌症治疗的抗性的患者中的癌症的方法
CN103435430A (zh) * 2013-08-08 2013-12-11 四川大学 一种还原酰胺类化合物的方法

Also Published As

Publication number Publication date
HRP20050788A2 (en) 2006-12-31
EP1603566A1 (en) 2005-12-14
TW200501955A (en) 2005-01-16
CA2518530A1 (en) 2004-09-23
PT1603566E (pt) 2009-04-27
ES2318276T3 (es) 2009-05-01
DE602004019193D1 (de) 2009-03-12
ATE421324T1 (de) 2009-02-15
AU2004218914A1 (en) 2004-09-23
RU2325159C2 (ru) 2008-05-27
MXPA05009687A (es) 2005-10-20
JP2006519807A (ja) 2006-08-31
TNSN05223A1 (en) 2007-06-11
IS8064A (is) 2005-10-10
MA27724A1 (fr) 2006-01-02
BRPI0408257A (pt) 2006-03-07
NO20054647D0 (no) 2005-10-10
WO2004080464A1 (en) 2004-09-23
RU2005131168A (ru) 2006-05-27
NO20054647L (no) 2005-12-09
EP1603566B1 (en) 2009-01-21
ZA200506571B (en) 2006-07-26
PL1603566T3 (pl) 2009-07-31
KR20050108383A (ko) 2005-11-16

Similar Documents

Publication Publication Date Title
CN1886378A (zh) 用于治疗增殖性疾病的用作raf激酶抑制剂的1,4－二取代的异喹啉衍生物
CN1152014C (zh) N-芳基邻氨基苯甲酸衍生物及其用途
CN1122668C (zh) 环氧噻酮衍生物，其制备方法及其药物组合物
CN100345830C (zh) 稠合杂芳基衍生物
CN1324022C (zh) 酪氨酸激酶抑制剂
CN1152031C (zh) 具有血管生成抑制活性的异喹啉衍生物
CN100343258C (zh) 新的4－氨基－5,6－取代的噻吩并[2,3－d]嘧啶化合物
CN1221262C (zh) 治疗炎性疾病的酞嗪衍生物
CN101052394A (zh) 使用二氢吲哚酮化合物治疗急性骨髓性白血病
HK1049011A1 (zh) 用於治疗局部缺血的化合物
CN1758910A (zh) 异喹啉衍生物治疗癌症和map激酶相关疾病的用途
CN1882580A (zh) 作为抗增殖药物的喹唑啉衍生物
CN1711089A (zh) 用于细胞增殖性障碍的二氢吲哚酮与化疗剂的联合给药
CN1768058A (zh) 作为黑皮质素受体激动剂的咪唑并吡啶衍生物
CN1711266A (zh) 具有抗增殖活性的嘧啶并化合物(ⅱ)
CN101031569A (zh) 作为人磷脂酰肌醇3－激酶δ抑制剂的喹唑啉酮
CN1115982A (zh) 具有药理学活性的吡啶类衍生物及其制备方法
CN1882570A (zh) 喹唑啉衍生物
CN1805748A (zh) 作为raf激酶抑制剂的2－氨基嘧啶衍生物
CN1543346A (zh) 新化合物
CN1173964C (zh) 新型苯并呋喃酮衍生物及其制备方法
CN1812986A (zh) 呋咱并苯并咪唑类化合物
CN1918160A (zh) 用作趋化因子受体活性调节剂的新颖三环螺环衍生物
CN101061101A (zh) 芳酰基呋喃和芳酰基噻吩
CN1863794A (zh) 作为血管生成抑制剂的喹唑啉衍生物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Open date: 20060412